prostate cancerMerkel cell carcinomasmall cell lung cancerbreast cancerneuroendocrine tumours
…-phase development to practice-changing trials, particularly in prostate cancer and neuroendocrine tumours. 51 In prostate cancer, the phase II…
17articles mentioning diseases
48disease mentions
1distinct diseases extracted
0%of mentions human-reviewed
Active filtersEntity: mCRPC ×
mCRPC
This disease is selected. Its supporting articles are shown below.
Articles mentioning mCRPC
17 articles · page 1 of 2mCRPCmetastatic castration-resistant prostate cancerprostate cancermelanomaipilimumab
…s with mCRPC.Methods Data were analyzed from n=27 patients with mCRPC treated with ipilimumab in a single-center clinical trial ( NCT…
Metastatic castration-resistant prostate cancer (mCRPC)mCRPCAB-3028
…Background Metastatic castration-resistant prostate cancer (mCRPC) remains a disease with low long-term survival, and while new mo…
mCRPCsolid tumorsmetastatic castration-resistant prostate cancer
…ty in vivo, supporting potential development as a treatment for mCRPC.…
metastatic castration-resistant prostate cancermCRPCpancreatic ductal carcinomaprostate canceripilimumabenzalutamideJ Clin OncolAtezolizumab
…al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. 2022;28:144–53.Koo KC, Pa…
advanced prostate cancermCRPCmetastatic castration-resistant prostate cancerdurvalumabolaparibabirateroneenzalutamideNCT02484404
…e (PARP) inhibition (PARPi) is a precision medicine strategy in advanced prostate cancer, with the greatest benefit seen in a subset of patients with ho…
prostate cancermCRPCSipuleucel-TUS Food and Drug AdministrationimmunotherapychemotherapiesProvengehormonal therapiesimmunotherapy-based
…ical trials of immunotherapy in metastatic castration-resistant prostate cancer (mCRPC) have largely been unsuccessful despite promising precli…
prostate cancermHSPCmCRPChigh risk biochemical recurrence177Lu-PSMA-617androgen receptor pathway inhibitorschemotherapypoly-ADP ribose polymerase (PARP) inhibitors
…177Lu-PSMA-617 in this disease space. Finally, as patients with prostate cancer are living longer, the review focuses on understanding and mana…
mCRPCmetastatic castration-resistant prostate cancerpembrolizumabArm AArm BpTVG-HP
…ater anti-tumor efficacy.Materials and methods 60 patients with mCRPC were treated with vaccine on days 1 and 8 of a 3 week cycle, wi…
Metastatic castration-resistant prostate cancer (mCRPC)mCRPCchimeric antigen receptor (CAR) T cell therapydnTGFβRIISTEAP2
…Background Metastatic castration-resistant prostate cancer (mCRPC) is a lethal, treatment-refractory stage of disease, frequently …
94.2%
mCRPCsolid tumorshematological malignanciesmetastatic castration-resistant prostate cancer (mCRPC)prostate tumorsAB-3028TCGAThe Cancer Genome AtlasGTExChimeric Antigen Receptor T (CAR T) cell therapies
…ns These collective data support the development of AB-3028 for mCRPC.…
metastatic castration-resistant prostate cancermetastatic castration-resistant prostate cancer (mCRPC)mCRPC177Lu-PSMA-617cyclophosphamideCyRPTNCT03873805
…, Pachter L, Forman SJ, Priceman SJ. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2024 Jun;30(6):1636-1644.Kostopoulos…